BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 30

• 

  Policy

  Sanders Seeks Subpoena for Novo Nordisk President Regarding Ozempic, Wegovy Pricing

  Sen. Bernie Sanders (I-Vt.), chair of the Senate health committee, has proposed issuing a subpoena to Novo Nordisk President Doug Langa forcing him to testify regarding the company’s pricing for Wegovy and Ozempic.

  June 12, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Policy

  FDA Action Alert: Merck, BMS, Sarepta and More

  The FDA has a packed calendar this week, with six decisions on the docket, including ones for Merck’s Keytruda, BMS’s Krazati and Sarepta’s Elevidys.

  June 12, 2024

   · 

  4 min read

   · 

  Tristan Manalac
• 

  Job Trends

  Massachusetts’ Life Sciences Job Growth Slows, but 10-Year Outlook Remains Strong: Report

  Although Massachusetts’ life sciences job growth increased by just 2.5% in 2023, the state continues to grow the industry, according to a new MassBioEd report.

  June 12, 2024

   · 

  4 min read

   · 

  Angela Gabriel
• 

  Job Trends

  7 Top Companies Hiring Associate Scientists

  Looking for associate scientist jobs in the biopharma industry? Check out these seven top companies hiring life sciences professionals like you.

  June 12, 2024

   · 

  1 min read

   · 

  Angela Gabriel
• 

  Drug Development

  Merck Eyes Next-Generation Obesity Drugs That Offer Additional Benefits

  Seeking to target the lucrative obesity market, Merck is focusing its R&D efforts on next-generation GLP-1 therapies that offer additional benefits beyond weight loss, according to company executives.

  June 12, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Biogen’s HI-Bio Buy Is Latest Biopharma Spending Spree in Projected $257B Immunology Market

  Biogen recently bolstered its pipeline with a potential $1.8 billion acquisition of Human Immunology Biosciences, following other big players looking to cash in on a global immunology market estimated to grow to $257 billion by 2032.

  June 12, 2024

   · 

  4 min read

   · 

  Tyler Patchen
• 

  Policy

  Teva Loses Inhaler Patent Case Against Amneal, Must Delete or Amend Orange Book Listing

  Teva Pharmaceuticals lost its patent row with Amneal Pharmaceuticals on Monday as a New Jersey court ruled that some of Teva’s claims over its inhaler product ProAir HFA were improperly listed on the FDA’s Orange Book.

  June 12, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Pfizer, Flagship Pioneering to Target Obesity Treatments Under 2023 Partnership

  Building on last year’s potential $7 billion partnership with Flagship Pioneering, Pfizer and Flagship-founded ProFound Therapeutics will work on discovering new obesity candidates.

  June 12, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Business

  Donanemab’s Promise, BIO Wrap and Mass Layoffs

  This week, an FDA adcomm unanimously voted for the approval of Eli Lilly’s anti-amyloid antibody as thousands of layoffs continue to rattle the industry.

  June 12, 2024

   · 

  1 min read

   · 

  Greg Slabodkin, Heather McKenzie, Tyler Patchen
• 

  Policy

  BIOSECURE Act Left Out of Department of Defense Spending Bill by House Rules Committee

  The BIOSECURE Act, which seeks to protect U.S. national security from Chinese biotech companies, will not be part of the House of Representatives vote on the 2025 fiscal year National Defense Authorization Act.

  June 12, 2024

   · 

  2 min read

   · 

  Tristan Manalac